Halozyme Therapeutics Option Alert: Mar 20 $75 Calls at the Ask: 1300 vs 180 OI; Earnings 10/30 After Close [est] 

Halozyme Therapeutics Option Alert: Mar 20 $75 Calls at the Ask: 1300 @ $4.0 vs 180 OI; Earnings 10/30 After Close [est] Ref=$65.5

Halozyme Therapeutics Bolsa (NASDAQ: HALO)

Halozyme Therapeutics

HALOZYME THERAPEUTICS INC

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

BGNE

HALO

2 acciones del sector de la salud muestran un RSI alto, lo que podría ser una advertencia clave para los inversores centrados en el momentum.

2 acciones de atención médica que podrían desplomarse en agosto

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics Inc

HALO COLLECTIVE INC by HALO COLLECTIVE INC.

Halo Collective Inc

Earnings

Press Releases

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications

Halozyme to Participate at Upcoming Investor Conferences

Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Halozyme Therapeutics Added to Russell 1000® Index

Halozyme to Report Second Quarter 2025 Financial and Operating Results

European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma

HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

Abivax

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

Caris Life Sciences

CRISPR Therapeutics

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Merus

Metsera

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Nuvalent

Vaxcyte

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Comments

Halozyme Therapeutics

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL